Curated News
By: NewsRamp Editorial Staff
November 04, 2026
Viromed's ViroCAP® med Wins Turkish Approval, Expands Global Reach
TLDR
- Viromed Medical AG secured early Turkish approval for ViroCAP med, gaining a strategic market edge with 7,000 binding orders through 2028.
- ViroCAP med uses contactless cold atmospheric plasma for one-to-two-minute wound treatments, now approved in Turkey with reimbursement talks underway.
- Viromed Medical AG advances cold plasma technology to treat open wounds and prevent infections, improving patient care and access in Turkey and beyond.
- Viromed Medical AG's ViroCAP med, approved in Turkey, applies cold plasma below 40 degrees Celsius for one to two minutes per treatment.
Impact - Why it Matters
This approval marks a significant step for Viromed in a strategically important healthcare market, with binding orders for 7,000 devices through 2028 signaling strong demand. The earlier-than-expected approval accelerates the commercial launch of ViroCAP® technology in Turkey and sets the stage for further expansion into Asia. The first reimbursement contract in Germany demonstrates real-world acceptance by payers, potentially paving the way for broader coverage. For patients, particularly those with open wounds or undergoing surgery, and those with LVADs at risk of infection, cold plasma therapy offers a contactless, quick treatment option. The ongoing studies and additional reimbursement discussions suggest growing recognition of cold plasma's clinical and economic value, which could lead to improved infection prevention and wound care outcomes.
Summary
Viromed Medical AG, a German medical technology company pioneering cold plasma technology, has received approval in Turkey for its medical device ViroCAP® med (MDR Class IIa). The approval, announced by CEO Uwe Perbandt, allows the product to be used for medical applications in Turkey, particularly for treating open wounds and intraoperative use. This milestone comes earlier than expected—initially forecast for February or March 2027—and follows the summer registration of ViroCAP® derma with Turkey's National Medical Device Tracking System (ÜTS). Viromed already holds binding minimum orders for 7,000 ViroCAP® derma/med devices through the end of 2028 for the Turkish market, with deliveries set to begin based on the new approval. The reimbursement process by Turkish health insurers is already underway, supporting the company's international expansion strategy.
In parallel, Viromed and its partner Umeco have initiated approval processes for ViroCAP® med in additional Asian countries, leveraging the product's prior EU MDR Class IIa certification. The company also achieved its first reimbursement by a statutory health insurer in Germany through a selective contract in Lower Saxony for treating patients with a left ventricular assist device (LVAD), focusing on preventing infections at the driveline exit site. Advanced discussions for further selective contracts in three other German federal states are ongoing. Additionally, a retrospective study on preventing postoperative wound infections will be published in November, and Viromed is launching a randomized study on ViroCAP® in LVAD patients and another on heart valve applications.
ViroCAP® med is designed for professional use by qualified medical personnel, supporting contactless and mobile cold atmospheric plasma treatment. Each application lasts one to two minutes while skin temperature remains below 40 degrees Celsius. Viromed, listed on the stock exchange since October 2022, focuses on distributing innovative cold plasma technology through its wholly owned subsidiary Viromed Medical GmbH and aims to advance cold plasma use in medicine. For more information, visit www.viromed-medical-ag.de.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Viromed's ViroCAP® med Wins Turkish Approval, Expands Global Reach
